Third, the exclusion of patients with diabetes mellitus was necessary to mitigate the confounding effects of the disease and its medications (e.g., GLP-1 receptor agonists, SGLT2 inhibitors) on weight and metabolic parameters. The gene discussed is SLC5A2; the disease is diabetes mellitus.